Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents-Reference-Cited by-同舟云学术

Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death–Ligand 1 Interaction as Potential Anticancer Agents

Published:2020-07-15 Issue:15 Volume:63 Page:8338-8358
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Cheng Binbin¹,Ren Yichang¹,Niu Xiaoge¹,Wang Wei¹,Wang Shuanghu¹^ORCID,Tu Yingfeng¹^ORCID,Liu Shuwen¹^ORCID,Wang Jin²,Yang Deying³,Liao Guochao³,Chen Jianjun¹^ORCID

Affiliation:

1. School of Pharmaceutical Sciences, Guangdong Provincial Key Laboratory of New Drug Screening, Southern Medical University, Guangzhou 510515, China

2. AbbVie Inc., North Chicago, Illinois 60064, United States

3. Joint Laboratory for Translational Cancer Research of Chinese Medicine of the Ministry of Education of the People’s Republic of China, International Institute for Translational Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou 510006, China

Funder

scientific research project of high level talents in Southern Medical University of China

Thousand Youth Talents Program from the Organization Department of the CPC Central Committee, China

International Science and Technology Cooperation Projects of Guangdong Province

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.0c00574

Reference48 articles.

1. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges